Bullfrog AI : Overview

Published: 2026-04-16 15:02:12 ET BFRG

Published on 04/16/2026 at 03:02 pm EDT

There are BIG problems in the industry

»S2OOB spent annually on pharma R&D with low return

on investment

-l23é success rate for drugs entering Phase l - high

failure, high cost 3

-5O3é of drugs fail phase 3

Smaller biotech's lack AI tools to analyze complex biomedical data

Urgent need for purpose-built, scalable AI solutions to boost efficiency and outcomes

Why Invest in BullFrog AZ?

•

Purpose-built proprietary AI platform driving scalable, efficient drug

discovery and optimal R&D results

•

Strategic partnerships fuel unlock of data driven insights and GNS

discoveries

•

Engaging big pharma for commercial deals; secured early commercial

validation

•

Executed first commercial agreement with a Top 5 pharma in lQ26; well-

positioned for scalable revenue opportunity

efficient model; structurally lean operations support high operating leverage

and profitable growth

Bolstered balance sheet to execute strategic priorities into late 2027; capital

enables precise

identification of key targets to significantly advance discovery

and clinical programs and access to innovative therapeutics

•

and improves the success of

drug development

Rooted in advanced technologies and methodologies from the

, we combine

precedent datasets and biological analytics to give

researchers clarity where traditional AI falls short

BullFrog AZ: life sciences intelligence

Unique Position in Rapidly Expanding Market

2.2x

BullFrog's AI design is well-positioned to capitalize across multiple industry

verticals to address demand for faster, lower GoSt drug development

Sector Market Growth Velocity Indicator

BullFrog AZ Innovation: Integrated AZ Platform for

Pharma R&D

teams can trust their inputs.

drivers of disease and treatment response.

•

that surround it

•

and

insight

winners and which succeed only under narrow conditions.

Addresses complex cross pharma industry challenges with AI at every step:

rapidly cleans, harmonizes, and structures true multimodal data so

•

goes beyond black-box predictions to reveal the true biological

•

identifies which drug target or clinical trial strategies are robust

•

BullFrog AZ + Top 5 Global Pharma Agreement

Achieves top-tier commercial validation of bfLEAP^ technology, positioned for

cross sell opportunities of pharma R&D foGused intelligence platform

global and commercial scale

validation of differentiated AI solution in pharma R&D

•

well-positioned to accelerate pharma

discovery in S8B+ market with complex indications

bfLEAP* identified target candidate

•

potential to expand end-

to-end AI platform across commercial therapeutic + R&D pipeline

near-term incentives aligned with access to

•

model designed to scale

commercial partners and drive revenue growth

"Major Depressive Disorder

Case Study: Powerful Value Proposition

BullFrog AI identified

in overall survival in patient subgroups through key

biomarkers in pancreatic cancer

BullFrog AI solutions identified key biomarker associated with

in survival in pancreatiG cancer

Low blood sugar " •

Study presented at the 2026 AmeriGan 9

Society of GliniGal Oncology (ASCO) Gastrointestinal CanGers Symposium ' (ASCO GI) and published in the Journal

of Glinical Oncology (JGO) supplement

Additional follow on collaboration with

●

leverage AI to analyze the largest natural history dataset ever collected from patients with facioscapulohumeral muscular dystrophy (FSHD)

Eleison Pharmaceuticals expeGted

" ,.","

- ..

..-,--_ . .

.- ...

Case Study: Commercial Access to Unique and

Proprietary Data for Novel Drug Target Discoveries

schizophrenia, and bipolar disorder

including major depressive disorder,

within neuropsychiatric disorders,

machine learning platform has identified

BullFrog AI's state-of-the-art causal AI and

provides for the

drug target discoveries

BullFrog AI's data partnership with LIBD

Access to 2,800 brain samples

Molecular insights into sGhizophrenia, bipolar

disorder, and major depressive disorder

tissue repository

neuropsychiatriG brain

LIBD is

●

leverage AI to analyze the largest natural history dataset ever collected from patients with facioscapulohumeral muscular dystrophy (FSHD)

Bullfrog AZ's scalable business model

Structure discovery and GliniGal trial optimization

deals with upfront fees, milestones, and royalties ("bio-bucks!)model).

AI solutions = scalable o to arket strate

Leverage internal GommerGial team and channel 11

partners to ramp adoption and revenue growth for

bfPREP^", bfLEAP^, and bfARENAS^'. , , * "

capabilities and solutions to the life sciences market.

Gontinue to innovate and provide unique proprietary

Operational & Strategic Growth Milestones

1026:

decisioning

analytics to

1026:

2026 shift tO Gommercialization and enterprise adoption, integrated platform

and early AI technology validation

Secured with a

to apply bfLEAP^ analytics platform to identify and prioritize

2027:

with Top 5 global pharmaceutical

delivering novel drug targets in MDD" results from drug targets to Iate-

stape clinical trial optimization

2026:

Strategic channel partners ramp revenue

across R&D with BullFrog's integrated drug intelligence platform

2026

2O27

2026:

commercial agreements,

large pharmaceutical companies

contracts, and partnerships with

"Major Depressive Disorder

Experienced Leadership

Institutional finance background with investment roles at Morgan Stanley and

Deutsche Asset Management; MBA in Finance from Golumbia Business School

Josh Blacher

•

Vin Singh

•

Thermo Fisher Scientific

business from Rutgers, RPI, and John Hopkins

Multi-disciplinary academic background with degrees in engineering and

The Dam Has Broken:

AZ Acquisition by Big Pharma

solutions model, shifting Big pharma to AI acquisitions and investments

NVIDIA and Lilly Announce Co-Innovation AI Lab to

Reinvent Drug Discovery in the Age of AI

Companies to Jointly Invest up to $1 Billion Over Five Years in Infrastructure and

Research

Big pharma partnering for AI solutions did not satisfy the need to own the AI